Pfizer, a pharmaceutical company, announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its ZAVZPRET nasal spray. This drug is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray that can treat migraine headaches in adults with or without an aura. The approval was based on two randomized, double-blind, placebo-controlled studies that showed the effectiveness, safety, and tolerability of ZAVZPRET in treating acute migraine attacks. The drug was well tolerated in clinical trials, and its most common side effects were taste disorders, nausea, nasal discomfort, and vomiting. It is contraindicated in patients with a history of hypersensitivity to zavegepant or any of its components. The drug is expected to be available in pharmacies in July 2023. Migraine affects nearly 40 million people in the United States and is the second leading cause of disability in the world, according to the World Health Organization. ZAVZPRET offers an alternative treatment option for people who need pain relief or cannot take oral medications due to nausea or vomiting.